A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Publication date: Aug 11, 2022

The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive Urothelial Carcinoma (UC) originating in the bladder who have high risk of recurrence.

Concepts Keywords
Drugs Leptomeningeal metastases protocol
Iv Cancer
Muscle Clinical medicine
Recruiting RTT
Urothelial Bristol-Myers Squibb
Monoclonal antibodies
Antineoplastic drugs
Nivolumab
Melanoma
Adjuvant therapy
Invasive urothelial carcinoma
Transitional epithelium

Semantics

Type Source Name
drug DRUGBANK Nivolumab
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Bladder Cancer
pathway KEGG Bladder cancer
disease MESH Carcinoma
disease MESH malignancy
disease MESH metastases

Original Article

Leave a Comment

Your email address will not be published.